Javitt, D. C. (2024). Mismatch Negativity (MMN) as a Pharmacodynamic/Response Biomarker for NMDA Receptor and Excitatory/Inhibitory Imbalance-Targeted Treatments in Schizophrenia. Neurophysiologic Biomarkers in Neuropsychiatric Disorders, 411–451. https://doi.org/10.1007/978-3-031-69491-2_15

Bulthuis, N. E., McGowan, J. C., Ladner, L. R., LaGamma, C. T., Lim, S. C., Shubeck, C. X., Brachman, R. A., Sydnor, E., Pavlova, I. P., Seo, D., Drew, M. R., & Denny, C. A. (2024). GluN2B on Adult-Born Granule Cells Modulates (R,S)-Ketamine’s Rapid-Acting Effects in Mice. International Journal of Neuropsychopharmacology, 27(10). https://doi.org/10.1093/ijnp/pyae036

Myers, S. J., Yuan, H., Perszyk, R. E., Zhang, J., Kim, S., Nocilla, K. A., Allen, J. P., Bain, J. M., Lemke, J. R., Lal, D., Benke, T. A., & Traynelis, S. F. (2023). Classification of missense variants in the N-methyl-d-aspartate receptor GRIN gene family as gain- or loss-of-function. Human Molecular Genetics, 32(19), 2857–2871. https://doi.org/10.1093/hmg/ddad104

Javitt, D. C., & Kantrowitz, J. T. (2022). The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to disease. Schizophrenia Research, 242, 56–61. https://doi.org/10.1016/j.schres.2022.01.013